Matevž Jan

Dr. Matevž Jan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
BGBorut Geršak
Borut Geršak
MZMichael O. Zembala
Michael O. Zembala
DMDirk Müller
Dirk Müller
TFThierry Folliguet
Thierry Folliguet
MJMatevž Jan
Matevž Jan
GWGerhard Wimmer-Greinecker
Gerhard Wimmer-Greinecker

28 August 2020 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
DŽDavid Žižek
David Žižek
BABor Antolič
Bor Antolič
TKTine Prolič Kalinšek
Tine Prolič Kalinšek
JŠJernej Štublar
Jernej Štublar
NKNina Kajdič
Nina Kajdič
MJMatevž Jan
Matevž Jan

1 November 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
BGBorut Geršak
Borut Geršak
MJMatevž Jan
Matevž Jan

26 September 2017 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
PPPetr Peichl
Petr Peichl
JBJakub Baran
Jakub Baran
DWDan Wichterle
Dan Wichterle
RČRobert Čihák
Robert Čihák
TSTomáš Skála
Tomáš Skála
JKJosef Kautzner
Josef Kautzner

6 June 2016 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
BABor Antolic
Bor Antolic
APAndrej Pernat
Andrej Pernat
MCMarta Cvijić
Marta Cvijić
DŽDavid Žižek
David Žižek
MJMatevž Jan
Matevž Jan
MŠMatjaž Šinkovec
Matjaž Šinkovec

24 April 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
DŽDavid Žižek
David Žižek
MMMiha Mrak
Miha Mrak
MJMatevž Jan
Matevž Jan
AMAnja Zupan Mežnar
Anja Zupan Mežnar
MIMaja Ivanovski
Maja Ivanovski
MŠMatjaž Šinkovec
Matjaž Šinkovec
Primary prevention patients with ischaemic cardiomyopathy and chronic total occlusion of an infarct-related coronary artery (CTO) are at a particularly high risk of implantable cardioverter-defibrillator (ICD) therapy occurrence. The trial was designed to evaluate the efficacy of preventive CTO-related substrate ablation strategy in ischaemic cardiomyopathy patients undergoing primary prevention ICD implantation. The PREVENTIVE VT study was a prospective, multicentre, randomized trial including ischaemic patients with ejection fraction ≤40%, no documented ventricular arrhythmias (VAs), and evidence of scar related to the coronary CTO. Patients were randomly assigned 1:1 to a preventive substrate ablation before ICD implantation or standard therapy with ICD implantation only. The primary outcome was a composite of appropriate ICD therapy or unplanned hospitalization for VAs. Secondary outcomes included the primary outcome’s components, the incidence of appropriate ICD therapies, cardiac hospitalization, electrical storm, and cardiovascular (CV) mortality. Sixty patients were included in the study. During the mean follow-up of 44.7 ± 20.7 months, the primary outcome occurred in 5 (16.7%) patients undergoing preventive substrate ablation and in 13 (43.3%) patients receiving only ICD [hazard ratio (HR): 0.33; 95% confidence interval (CI): 0.12–0.94; P = 0.037]. Patients in the preventive ablation group also had fewer appropriate ICD therapies (P = 0.039) and the electrical storms (Log-rank: P = 0.01). While preventive ablation also reduced cardiac hospitalizations (P = 0.006), it had no significant impact on CV mortality (P = 0.151). Preventive ablation of the coronary CTO-related substrate in patients undergoing primary ICD implantation is associated with the reduced risk of appropriate ICD therapy or unplanned hospitalization due to VAs. Preventive ablation of coronary total occlusion-related substrate at the time of primary prevention defibrillator implantation is associated with a reduced risk of appropriate defibrillator therapy or unplanned hospitalization due to ventricular arrhythmias.